All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following hospital-treated infection patient populations:

  • Diagnosed HCAP events due to E.coli
  • Diagnosed BSI events due to Klebsiella
  • Diagnosed BSI events due to E.coli
  • Diagnosed BSI events due to Pseudomonas
  • Diagnosed BSI events due to other gram-negative
  • Diagnosed cIAI events due to E.coli
  • Diagnosed cIAI events due to Pseudomonas
  • … and many more (details available on request).

Note: Coverage may vary by country and region.

Table of contents

  • Hospital-Treated Gram-Negative Infections - Epidemiology - Emerging Markets Data
    • Introduction
      • Key Findings
        • UTI Events per 1,000 in 2016 and 2026
        • Relative Sizes of the Contributing Factors to the Trend in UTI Events over the Next Ten Years
    • Epidemiology Data
    • Methods
      • Diagnosed UTI Events
      • Diagnosed NP Events
      • Diagnosed BSI Events
      • Diagnosed cIAI Events
      • Diagnosed cSSSI Events
      • Diagnosed SSI Events
      • Hospital-Treated Gram-Negative Infections Pathogen Distribution
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Hospital-Treated Infections
        • Studies Excluded from the Analysis of Hospital-Treated Infections
      • Risk/Protective Factors
        • Risk/Protective Factors for Hospital-Treated Infections
      • Bibliography

Author(s): Fjoralba Kristo, M.D., M.P.H. ; Lade Ayodele

Fjoralba Kristo, M.D., M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she completed a postdoctoral fellowship at the University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as a research scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Dr. Kristo holds an M.P.H. degree from Boston University School of Public Health, with a concentration in epidemiology and biostatistics, and a medical degree from the University of Medicine in Bucharest, Romania.

Lade Ayodele, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she researched antiretroviral therapy funding, availability, and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts. She holds a master's degree in public health (quantitative methods concentration) from Harvard University and a medical degree from the University of Ibadan in Nigeria. She is pursuing a Ph.D. in epidemiology at Boston University School of Public Health, with a focus on pharmacoepidemiology.